A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent.
Gioelli N, Maione F, Camillo C, Ghitti M, Valdembri D, Morello N, Darche M, Zentilin L, Cagnoni G, Qiu Y, Giacca M, Giustetto M, Paques M, Cascone I, Musco G, Tamagnone L, Giraudo E, Serini G.
Gioelli N, et al. Among authors: serini g.
Sci Transl Med. 2018 May 23;10(442):eaah4807. doi: 10.1126/scitranslmed.aah4807.
Sci Transl Med. 2018.
PMID: 29794061
Free article.